CoCo Therapeutics is a United Kingdom-based biotechnology company formed in 2013 jointly by King's College London, the Wellcome Trust and Advent Venture Partners.[1] The company will focus on development of therapeutics for Alzheimer's disease which target retinoic acid receptor alpha,[1] specifically building on work originating in the Neuroscience Drug Discovery Unit of King's College, led by Jonathan Corcoran.[2] This work was funded through the Wellcome Trust's Seeding Drug Discovery Initiative.[3]
| Industry | Pharmaceutical industry |
|---|---|
| Founded | United Kingdom (2013) |
| Headquarters | United Kingdom |
| Website | cocotherapeutics |
References
edit- ^ a b "New U.K. Biotech Firm CoCo Therapeutics Takes on Alzheimer's". Genetic Engineering & Biotechnology News (paper). 1 April 2013. p. 12.
- ^ "New drug discovery company for Alzheimer's research" (Press release). King's College University. 3 April 2013. Retrieved 4 July 2013.
- ^ "Company created to progress experimental Alzheimer's disease therapy" (Press release). Wellcome Trust. 5 March 2013. Retrieved 4 July 2013.
 | This article about a company of the UK is a stub. You can help Wikipedia by expanding it. |